Начало › Рак на белия дроб с недребноклетъчен тип › Мичиган › Ann Arbor
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Ann Arbor, MI
26 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Ann Arbor (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- и още 4
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Набиране на участнициФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- Chelsea Hospital, Chelsea · на 15 мили
- и още 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- University of Michigan Rogel Cancer Center, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 мили
- и още 2
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- Trinity Health Ann Arbor Hospital, Ann Arbor
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti · на 7 мили
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Набиране на участнициФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- и още 4
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1
- University of Michigan Health Systems, Ann Arbor
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Набиране на участнициФаза 1/2
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Ann Arbor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of Michigan, Ann Arbor
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- University of Michigan, Ann Arbor
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- University of Michigan, Ann Arbor
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Набиране на участнициФаза 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552), Ypsilanti · на 7 мили
Gilteritinib for the Treatment of ALK NSCLC
Набиране на участнициФаза 1
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Набиране на участнициФаза 1
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010, Ann Arbor
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- и още 4
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 мили
- и още 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea · на 15 мили
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton · на 18 мили
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · на 7 мили
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · на 7 мили
- и още 4
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Набиране на участнициФаза 1/2
- University of Michigan, Ann Arbor
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Repositioning Immunotherapy in VetArans With Lung Cancer
Набиране на участнициФаза 2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- University of Michigan (Data Collection Only), Ann Arbor
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Набиране на участници
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 1/2
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Ann Arbor
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Ann Arbor
- Рак на гърдата27 проучвания
- Рак на простатата27 проучвания
- Рак (всички видове)25 проучвания
- Рак на белия дроб23 проучвания
- Колоректален рак23 проучвания
- Сърдечна недостатъчност22 проучвания
- Остра миелоидна левкемия17 проучвания
- Сърдечно-съдово заболяване16 проучвания
- Рак на панкреаса14 проучвания
- Меланом12 проучвания
- Инсульт12 проучвания
- Плоскоклетъчен карцином на главата и шията12 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.